Prevalence of c-myc expression in breast lesions associated with microcalcifications detected by routine mammography

Sao Paulo Medical Journal

Volumn 127, Issue 2, 2009, Pages 66-70

  Mazzini, Renato Coimbra ^a,b   Elias, Simone ^a   Nazário, Afonso Celso Pinto ^a   Kemp, Cláudio ^a   Loggullo, Ângela Flavia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Escola Paulista de Medicina ^*  (Brazil)

Author keywords

Biopsy, needle; Breast neoplasms; Gene expression; Mammography; Proto oncogene proteins c myc

Indexed keywords

BIOTIN; MYC PROTEIN; PEROXIDASE; STREPTAVIDIN;

ARTICLE; BENIGN TUMOR; BREAST CALCIFICATION; BREAST LESION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PERCUTANEOUS BIOPSY; PREVALENCE; PROTEIN EXPRESSION;

ADULT; BREAST NEOPLASMS; CALCINOSIS; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; MAMMOGRAPHY; PRECANCEROUS CONDITIONS; PREVALENCE; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES;

EID: 70349582187     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802009000200003     Document Type: Article

References (39)

1. Harris JR, Morrow ME, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven; 1996.
2. Sickles EA. Breast imaging: from 1965 to the present. Radiology. 2000;215(1):1-16.
3. Kopans DB. Breast imaging. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
4. Fondrinier E, Lorimier G, Guerin-Boblet V, Bertrand AF, Mayras C, Dauver N. Breast microcalcifications: multivariate analysis of radiologic and clinical factors for carcinoma. World J Surg. 2002;26(3):290-6.
5. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20(6):479-89.
6. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11(3):167-80.
7. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol. 1994;11(3):199-207.
8. Brenner RJ. Lesions entirely removed during stereotactic biopsy: preoperative localization on the basis of mammographic landmarks and feasibility of freehand technique - initial experience. Radiology. 2000;214(2):585-90.
9. Liberman L. Centennial dissertation. Percutaneous imaging-guided core breast biopsy: state of the art at the millennium. AJR Am J Roentgenol. 2000;174(5):1191-9.
10. Tibiletti MG, Sessa F, Bernasconi B, et al. A large 6q deletion is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and carcinomas of the breast. Clin Cancer Res. 2000;6(4):1422-31.
11. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2000;7(3):143-64.
12. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99-109.
13. Brown AM. Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res. 2001;3(6):351-5.
14. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837-51.
15. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998;3:d250-68.
16. Packham G, Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta. 1995;1242(1): 11-28.
17. Hoffman B, Liebermann DA. The proto-oncogene c-myc and apoptosis. Oncogene. 1998;17(25):3351-7.
18. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1-11.
19. Elend M, Eilers M. Cell growth: downstream of Myc - to grow or to cycle? Curr Biol. 1999;9(24):R936-8.
20. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999;18(19):2967-87.
21. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 1999;59(7 Suppl):1685s-1692s.
22. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-95.
23. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004-16.
24. American College of Radiology (ACR). BI-RADS® - Mammography. 4th ed. Reston: American College of Radiology; 2003. Available from: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/ BIRADSAtlas/BIRADSAtlasexcerptedtext/BIRADSMammographyFourthEdition.aspx. Accessed in 2009 (Mar 17).
25. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol. 1999;187(3):272-8.
26. Page DL, Steel CM, Dixon JM. ABC of breast diseases. Carcinoma in situ and patients at high risk of breast cancer. BMJ. 1995;310(6971):39-42.
27. Cole MD. Activation of the c-myc oncogene. Basic Life Sci. 1986;38:399-406.
28. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998;82(8): 1513-20.
29. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995;175(2):195-201.
30. Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 1997;80(9):1740-5.
31. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev. 1993;3(1): 44-9.
32. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature. 1987;328(6129):445-9.
33. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 2000;83(12):1688-95.
34. Ioachim E, Charchanti A, Briasoulis E, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002;38(18):2362-70.
35. Mai S. Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene. 1994;148(2):253-60.
36. Schmitt FC, Reis-Filho JS. c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? Breast Cancer Res. 2003;5(4): 188-91.
37. Le Roy X, Escot C, Brouillet JP, et al. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene. 1991;6(3):431-7.
38. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992;52(5):1107-13.
39. Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol. 1995;31B(6):384-91.